The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns
| العنوان: | The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns |
|---|---|
| المؤلفون: | Markku Partinen, Daniel Weibel, Cormac J. Sammon, Henrik Svanström, Salvatore Ferro, Anders Hviid, Corinne S de Vries, Mees Mosseveld, Leonoor Wijnans, Harald Heijbel, Piotr Kramarz, Coralie Lecomte, Martijn J. Schuemie, Lisen Arnheim Dahlström, Ditte Mølgaard-Nielsen, Angelo Menna, Francesco Trotta, Sebastiaan Overeem, Carmela Santuccio, Pär Sparén, Jonas Hällgren, Nicoline A.T. van der Maas, Miriam C. J. M. Sturkenboom, Keivan Kaveh Moghadam, Gert Jan Lammers, Silvana Romio, Jan Bonhoeffer, Kari Johansen, Poul Jennum, Giuseppe Plazzi |
| المساهمون: | Medical Informatics, L. Wijnan, C. Lecomte, C. d. Vrie, D. Weibel, C. Sammon, A. Hviid, H. Svanström, D. Mølgaard-Nielsen, H. Heijbel, L. A. Dahlström, J. Hallgren, P. Sparen, P. Jennum, M. Mosseveld, M. Schuemie, N. v. der, M. Partinen, S. Romio, F. Trotta, C. Santuccio, A. Menna, G. Plazzi, K. K. Moghadam, S. Ferro, G. J. Lammer, S. Overeem, K. Johansen, P. Kramarz, J. Bonhoeffer, M. C. J |
| المصدر: | Vaccine, 31, 8, pp. 1246-54 Vaccine, 31(8), 1246-1254. Elsevier Vaccine, 31(8), 1246-1254 Vaccine, 31, 1246-54 |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | Male, Pediatrics, Cataplexy, Background rates, 80 and over, Child, Child, immunology, Cohort Studies, Influenza A Virus, H1N1 Subtype, Epidemiology, Pandemic, 80 and over, Influenza A Virus, Pandemrix, Preschool, Cohort Studies, Europe, adverse effects/methods, Young Adult, Child, Adolescent, Adult, Aged, Preschool, Europe, epidemiology, Female, Humans, Infant, Newborn, H1N1 Subtype, Influenza Vaccines, administration /&/ dosage/adverse effects, Influenza, Human, prevention /&/ control/virology, Middle Aged, Narcolepsy, Retrospective Studies, Vaccination, adverse effects/methods, Young Adult, administration /&/ dosage/adverse effects, Influenza, Aged, 80 and over, Influenza vaccine, Incidence (epidemiology), Newborn, Influenza A Viru, Incidence, epidemiology, Female, Humans, Infant, Infant, prevention /&/ control/virology, Male, Middle Aged, Narcolepsy, Infectious Diseases, Child, Preschool, Molecular Medicine, medicine.symptom, epidemiology, Retrospective Studies, Vaccination, Cohort study, medicine.medical_specialty, DCN MP - Plasticity and memory, SDG 3 - Good Health and Well-being, Influenza, Human, medicine, immunology, Influenza Vaccine, General Veterinary, General Immunology and Microbiology, business.industry, Public Health, Environmental and Occupational Health, Infant, Newborn, Adolescent, Adult, Aged, Aged, ASO3B adjuvant, business |
| الوصف: | Contains fulltext : 117810.pdf (Publisher’s version ) (Closed access) BACKGROUND: In August 2010 reports of a possible association between exposure to AS03 adjuvanted pandemic A(H1N1)pdm09 vaccine and occurrence of narcolepsy in children and adolescents emerged in Sweden and Finland. In response to this signal, the background rates of narcolepsy in Europe were assessed to rapidly provide information for signal verification. METHODS: We used a dynamic retrospective cohort study to assess the narcolepsy diagnosis rates during the period 2000-2010 using large linked automated health care databases in six countries: Denmark, Finland, Italy, the Netherlands, Sweden and the United Kingdom. RESULTS: Overall, 2608 narcolepsy cases were identified in almost 280 million person years (PY) of follow up. The pooled incidence rate was 0.93 (95% CI: 0. 90-0.97) per 100,000 PY. There were peaks between 15 and 30 year of age (women>men) and around 60 years of age. In the age group 5-19 years olds rates were increased after the start of pandemic vaccination compared to the period before the start of campaigns, with rate ratios (RR) of 1.9 (95% CI: 1.1-3.1) in Denmark, 6.4 (95% CI: 4.2-9.7) in Finland and 7.5 (95% CI: 5.2-10.7) in Sweden. Cases verification in the Netherlands had a significant effect on the pattern of incidence over time. CONCLUSIONS: The results of this incidence study provided useful information for signal verification on a population level. The safety signal of increased narcolepsy diagnoses following the start of the pandemic vaccination campaign as observed in Sweden and Finland could be observed with this approach. An increase in narcolepsy diagnoses was not observed in other countries, where vaccination coverage was low in the affected age group, or did not follow influenza A(H1N1)pdm09 vaccination. Patient level analyses in these countries are being conducted to verify the signal in more detail. |
| وصف الملف: | ELETTRONICO; application/pdf |
| تدمد: | 0264-410X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcd568eb131c518046042fe84950dd6bTest https://hdl.handle.net/2066/117810Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....fcd568eb131c518046042fe84950dd6b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 0264410X |
|---|